However, we believe that peripheral cytokines are a fundamentally noisy variable and that this fact must be taken into account when considering the implications of any cytokine study
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
10.1104/pp.99.4.1461 Plant Physiol
Transitioning to maintenance dosing (0.25mg twice weekly) instead of stopping abruptly sustains 8085% of peak pigmentation indefinitely JAMA Dermatology research found biweekly dosing retained colour for up to 60 days without further loading